New combo therapy for metastatic breast cancer shows promise in early trial

NCT ID NCT01658462

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study tested whether adding the drug nintedanib to standard chemotherapy (docetaxel) helps people with HER2-negative breast cancer that has spread or come back. 51 adults participated. The main goal was to see if the combination slowed cancer growth for at least 6 months. Researchers also tracked side effects, overall survival, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CH Compiègne-Noyon

Compiègne, 60200, France
CHU Amiens- Hôpital Sud

Amiens, 80 054, France
CMCO de la Côte d'Opale

Saint-Martin-Boulogne, 62280, France
Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54 500, France
Centre Léonard de Vinci

Dechy, 59 187, France
Centre Oscar Lambret

Lille, 59 020, France
Centre Pierre Curie

Beuvry, 62660, France
Hôpital Bretonneau

Tours, 37044, France
Hôpital Privé les Bonnettes

Arras, 62000, France
Institut Jean Godinot

Reims, 51056, France
Nouvelle Clinique des Dentellières

Valenciennes, 59300, France
Polyclinique de Limoges - site Chénieux

Limoges, 87039, France

Conditions

Explore the condition pages connected to this study.

BREAST CANCER